Coya to meet with FDA about a Phase 2 trial of COYA 302 for ALS
Coya Therapeutics is planning to file a request with the U.S. Food and Drug Administration (FDA) to continue testing its investigational therapy COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS) in a Phase 2 clinical trial. The company is preparing a meeting with the regulatory agency…